FDA, NIH Gene Therapy Oversight Roles To Be Questioned By Rep. Waxman
Executive Summary
Rep. Waxman (D-Calif.) plans to ask FDA how the agency balances the proprietary rights of sponsors with the expectation of greater public scrutiny of gene therapy trials.